Biotech Stocks Facing FDA Decision In June 2020

1 / 14

The FDA has been focusing mainly on COVID-19-related review since March. But that said, the regulatory decision on drugs proposed for rare tumors and life-threatening diseases has not been deferred.

So far this year, 20 novel drugs have won the FDA stamp of approval compared to 11 during the same period in 2019. The number of novel drugs approved for the full year of 2019 was 48.

Now, let’s take a look at the biotech stocks awaiting a regulatory decision in the month of June.